Yes, I am anxious to hear of the approval of advancement to cohort 4, I think this is where dosing wise things are really starting to ramp up, and hopefully patients are starting to see some very noticable or even dramatic results. Having all this data wrapped up by ASCO would be great, but for us longs that are here until the end game, the only bottom line that matters in the end is that the trial is a success in meeting all primaryand secondary endpoints no matter what time frame that happens on.

Here's to another "boring" but great day of patients continuing to get their dosing of Kevetrin from the smart and hard working folks at DF.